New weight-loss drugs coming in 2026-2027

TL;DR

• Two of the new wave are now actually approved: orforglipron, the first oral small-molecule GLP-1, cleared by the FDA as Foundayo in April 2026; and the oral Wegovy tablet (once-daily oral semaglutide), the first oral GLP-1 approved for weight management, which launched in the US in January 2026.
• Retatrutide leads on efficacy and remains investigational - the four core TRIUMPH trials have reported (TRIUMPH-2 and TRIUMPH-3 both met their goals against placebo in July 2026), Lilly plans to file in Q1 2027 but had not filed as of 26 October 2026, and the FDA says it cannot legally be used in compounding. TRIUMPH-5, the randomised head-to-head against tirzepatide, has not reported.
• CagriSema was filed with the FDA in December 2025 and is still under review, with Novo pointing to a decision in Q4 2026 - none had been issued as of 26 October 2026, and no decision date (PDUFA date) has been made public. Its head-to-head trial against tirzepatide (REDEFINE-4) missed its primary endpoint. Amycretin is in Phase 3 with approval around 2028.
• Three oral small molecules now exist: orforglipron (approved), aleniglipron (Phase 2b, August 2026) and AstraZeneca's elecoglipron (Phase 2b June 2026, now entering Phase III).
• Dosing interval is the other axis: Amgen's MariTide (Phase 3) and Pfizer's PF'3944 (Phase 2b) both target monthly injection, and both are investigational with no lawful supply route.
• Don't stop something that's working to wait - most of the pipeline is years from a pharmacy, and every comparison between these compounds is cross-trial, not head-to-head.

Updated October 2026: status re-checked 26 October 2026. Retatrutide: TRIUMPH-2 and TRIUMPH-3 met their primary endpoints against placebo (23 July 2026), and the Q1 2027 BLA is still planned, not filed. CagriSema: still under FDA review, Q4 2026 decision expected by the company, no public PDUFA date, not approved. Replaces a supply-verification CTA with plain status links and a bloodwork-first recommendation.

Updated September 2026: full status sweep. Adds the oral Wegovy tablet (once-daily oral semaglutide) as the second approved oral GLP-1 in the table; confirms CagriSema is still under review with no FDA decision as of 15 September 2026 and adds the REDEFINE-4 head-to-head miss against tirzepatide; and states plainly that TRIUMPH-5, the only randomised retatrutide-versus-tirzepatide comparison, has not reported, so every retatrutide-versus-tirzepatide figure in circulation is cross-trial.

Updated September 2026: adds two investigational candidates missing from the map: AstraZeneca's oral small-molecule elecoglipron, which moved into a Phase III programme on 8 June 2026 after its VISTA and SOLSTICE Phase 2b trials reported at ADA 2026 and published in The Lancet, and Pfizer's ultra-long-acting injectable GLP-1 receptor agonist PF'3944, which reported Phase 2b monthly-dosing results in 2026. Neither is approved in any market.

Updated September 2026: adds aleniglipron, a second oral small-molecule GLP-1 candidate that reported Phase 2b results in August 2026; corrects the retatrutide filing line to match Lilly's stated Q1 2027 BLA intent; and adds a last-reviewed date.

---

The first generation - semaglutide and tirzepatide - turned obesity treatment into a blockbuster. The next generation is a genuine step-change, and it's arriving fast. The shift has four themes: multi-target drugs (hitting two or three hunger and metabolism pathways at once), oral options (pills instead of weekly shots), longer dosing (monthly injections), and muscle preservation (losing fat without the lean-mass cost). Some of these produce weight loss that rivals or surpasses bariatric surgery. Here's what's coming, honestly - including the fact that most of it isn't approved yet, and the best drug is usually the one you can start today.

2026 regulatory status (checked 26 October 2026). The four core TRIUMPH trials have now reported, with TRIUMPH-2 (type 2 diabetes) and TRIUMPH-3 (established heart disease) both meeting their primary endpoints against placebo on 23 July 2026. Lilly says it is finishing the manufacturing and quality package and plans to submit a Biologics License Application to the FDA in Q1 2027; it has not been submitted yet. A planned submission is not a submission, and a submission is not an approval: retatrutide is not approved in any market, and the FDA has stated it is not a component of an approved drug and cannot legally be used in compounding. The cardiovascular outcomes trial runs to 2028–2029. The general form of that distinction - why filed, approved and available are three different dates - is the single most useful thing to hold in mind while reading the table below.

The head-to-head that does not exist yet. TRIUMPH-5 is the first and only randomised trial designed to compare retatrutide directly against tirzepatide, with percent change in body weight as its primary outcome. As of 26 October 2026 it has not reported, and the earliest credible readout is 2027 onward. That matters because every "retatrutide beats tirzepatide" figure currently circulating is assembled from separate trials with different populations, durations and endpoints - which is not a head-to-head result and cannot substitute for one. The same caution applies in the other direction: CagriSema's head-to-head against tirzepatide, REDEFINE-4, did run, and it failed to show non-inferiority on weight loss at 84 weeks - a reminder that when a real head-to-head finally happens, it sometimes contradicts the cross-trial expectation. If that distinction is new to you, what a study actually measured is the place to start.

The pipeline at a glance

New this cycle: aleniglipron, and what a Phase 2b result actually is

In August 2026, Nature Medicine published the Phase 2b results for aleniglipron, a once-daily oral small-molecule GLP-1 receptor agonist - not a peptide, not an injection. The trial randomised 230 adults with obesity or overweight across 38 US centres to one of three dose levels for 36 weeks. Mean body-weight change from baseline ranged from −9.0% to −12.1% across the three dose groups studied; the placebo-adjusted figures were −8.2% to −11.3%. Gastrointestinal side effects were reported as mostly mild to moderate and became less frequent over the trial.

Three things are worth holding steady about that result:

• It is Phase 2b. A 230-person mid-stage trial establishes that a compound is worth taking into Phase 3. It does not establish long-term safety, durability, or effect in the broader population that a registrational programme is designed to test.
• 36 weeks is not a durability figure. Weight-loss curves in this class typically have not plateaued by nine months, and what happens after treatment stops is a separate question entirely.
• It is not approved anywhere, and there is no lawful supply route - not by prescription, not by compounding.

Read against orforglipron, aleniglipron is confirmation of a direction rather than a leapfrog: "oral GLP-1" now describes two distinct chemistries - a peptide in a pill (oral semaglutide) and a small molecule (orforglipron, aleniglipron) - and the small-molecule route is the one that scales. Any comparison between these compounds is cross-trial, not head-to-head, and cross-trial comparison is not evidence of superiority. The full picture is in the aleniglipron explainer and oral versus injectable GLP-1s.

Also new this cycle: elecoglipron, and a monthly injectable from Pfizer

Two further investigational candidates belong on this map, and neither is approved in any market.

Elecoglipron (AstraZeneca) - a third oral small-molecule GLP-1. On 8 June 2026, AstraZeneca reported results from two Phase 2b trials - VISTA, in adults with obesity or overweight, and SOLSTICE, in adults with type 2 diabetes - at the American Diabetes Association Scientific Sessions, with simultaneous publication in The Lancet. In VISTA, the highest dose arm studied showed a mean body-weight reduction of about 10.5% at 26 weeks versus roughly 0.6% on placebo, continuing to around 11.8% at 36 weeks. In SOLSTICE, mean HbA1c fell about 1.9 percentage points from baseline at 26 weeks versus 0.2 on placebo. On the strength of those results AstraZeneca said it is advancing elecoglipron into an extensive Phase III programme across obesity and type 2 diabetes, including cardiovascular and kidney outcome trials. The Phase III programme is a decision to run registrational trials, not a result from them - elecoglipron is investigational and is not approved anywhere.

Pfizer's PF'3944 - an injection you'd take monthly, not weekly. Pfizer reported Phase 2b results in 2026 for PF'3944, an ultra-long-acting injectable GLP-1 receptor agonist designed to move patients onto monthly maintenance injections. In the VESPER-3 trial, participants switched from weekly to monthly injection during the study, and the company reported up to about 12.3% mean placebo-adjusted weight loss at week 28. Pfizer has said Phase 3 work is advancing. Again: Phase 2b, investigational, not approved in any market.

Three cautions apply to both. These are mid-stage results, and mid-stage results routinely shrink or fail in Phase 3. Any comparison between these compounds and the approved drugs is cross-trial, not head-to-head - different populations, different durations, different endpoints - and cross-trial comparison is not evidence of superiority. And neither has a lawful supply route: not by prescription, not by compounding, anywhere.

The four shifts driving it

1. From one hormone to two or three. First-gen drugs mostly acted on GLP-1. New drugs increasingly activate two or three metabolic pathways simultaneously, leading to greater weight loss - GIP, amylin and glucagon are the added targets, each adding a different lever (appetite, satiety, energy expenditure). This is why the newest agents report mean weight loss above 20% in their trials, where the first generation sat lower.

2. Pills, not just shots. New small-molecule drugs like orforglipron - and now the investigational aleniglipron and elecoglipron behind it - may eliminate injections and increase accessibility, and because a small molecule is easier to mass-produce than an injectable peptide, oral options could also ease the supply and cost problems that have dogged this class. Amycretin aims to bring a multi-mechanism approach into pill form.

3. Monthly, not weekly. Amgen's MariTide is designed for monthly dosing - a big adherence gain over weekly injections - and Pfizer's investigational PF'3944 is being developed toward the same monthly interval. Both are unapproved; the goal is fewer injections a year, not a stronger one.

4. Protecting muscle, and going beyond weight. Newer agents are being designed to preserve lean mass (a real weakness of rapid weight loss) and to treat linked conditions - survodutide for MASH (fatty liver disease), others for cardiovascular and sleep-apnea outcomes. Obesity treatment is becoming metabolic-health treatment.

The honest part: should you wait?

Tempting as the pipeline is, most of it is investigational and years from your pharmacy - retatrutide's approval sits no earlier than the 2027–28 window, amycretin around 2028, aleniglipron and Pfizer's PF'3944 further out still, and elecoglipron only now entering the Phase III trials that would support a filing - and even the filed ones face review. Meanwhile the drugs available now are highly effective. The sensible framing from obesity medicine: don't stop something that's working to wait for the next thing. The newest molecule on a slide isn't better than the approved one you can start under supervision today - and none of these, present or future, replaces the muscle-protection and monitoring that make the results durable and safe.

The bottom line - and where to start

The 2026–27 pipeline is a real leap: triple agonists (retatrutide) pushing toward surgical-level results, combinations (CagriSema), oral multi-mechanism drugs (amycretin, orforglipron, aleniglipron, elecoglipron), monthly dosing (MariTide, PF'3944), and a shift toward muscle preservation and metabolic health. But most is unapproved and years out, and the best move is rarely to wait - it's to start with what is approved now, with your own doctor, and adjust as the field evolves.

Where Vivre Labs fits

Vivre Labs offers semaglutide and tirzepatide, both approved prescription medicines for weight management, and keeps a retatrutide page that sets out its status as investigational and not approved. Whichever direction you are leaning, we recommend starting with baseline bloodwork, so the decision begins from measured numbers.

Frequently asked questions

What is the strongest weight-loss drug coming? By trial data, the triple agonist retatrutide leads the next generation, with Phase 3 weight loss approaching the range once reserved for bariatric surgery. It's investigational, with a stated BLA submission in Q1 2027 and approval no earlier than 2027–28. Among approved drugs, tirzepatide remains the most effective today.

Will there be a weight-loss pill as strong as the injections? There are now two approved oral GLP-1s for weight management, and they are different chemistries. Oral Wegovy is a peptide - semaglutide in tablet form - approved for weight management and reduction of major adverse cardiovascular event risk, and it launched in the US in January 2026; its OASIS-4 weight-loss result was broadly comparable to injectable Wegovy in participants who stayed on treatment. Orforglipron (Foundayo) is a small molecule, so it carries no food or water restrictions, but its trial weight loss sits lower. Amycretin (an oral GLP-1/amylin) and aleniglipron (a second oral small molecule, still Phase 2b) are behind both. The old shorthand that "pills trade efficacy for convenience" is now only partly true: it holds for the small molecules, less so for the oral peptide.

Has CagriSema been approved? Not as of 26 October 2026. Novo Nordisk filed the NDA in December 2025 on REDEFINE-1 and REDEFINE-2, and the company points to an FDA decision in Q4 2026; no decision date has been made public. One result worth knowing while you wait: REDEFINE-4, the head-to-head against tirzepatide, did not meet its primary endpoint of non-inferiority on weight loss at 84 weeks. That does not mean CagriSema is ineffective - REDEFINE-1 showed substantial weight loss against placebo - but it does mean the cross-trial expectation that it would match or beat tirzepatide was not borne out when the two were actually compared.

Has the retatrutide-versus-tirzepatide trial reported? No. TRIUMPH-5 is the randomised head-to-head and it had not reported as of 26 October 2026; the earliest credible readout is 2027 onward. Any figure presented today as a retatrutide-versus-tirzepatide comparison is drawn from separate trials in different populations.

What is aleniglipron, and can I get it? It's an investigational once-daily oral small-molecule GLP-1 receptor agonist that reported Phase 2b results in August 2026. It is not approved in any market, is not available by prescription, and is not eligible for compounding. Anything offered for sale under that name is not a legitimate supply of the trial compound.

What is elecoglipron? An investigational oral small-molecule GLP-1 receptor agonist from AstraZeneca. Its Phase 2b VISTA and SOLSTICE trials reported at ADA 2026 and published in The Lancet, and the company moved it into a Phase III programme in June 2026. It is not approved in any market and is not available by prescription or compounding.

Is there a monthly weight-loss injection yet? Not an approved one. Amgen's MariTide and Pfizer's PF'3944 are both investigational injectables aimed at monthly dosing; PF'3944 reported Phase 2b results in 2026. Every approved injectable in this class today is dosed more often than monthly, and neither monthly candidate can be lawfully supplied anywhere.

Should I wait for the new drugs? Usually not. The effective approved drugs are available now, most pipeline options are years from approval, and stopping something that works to wait rarely makes sense. A clinician can flag when a coming option would genuinely change your plan.

Related reading

• Aleniglipron · Retatrutide · CagriSema · When will CagriSema be approved? · Amycretin · Orforglipron · Tirzepatide · Semaglutide
• Oral versus injectable GLP-1s - how the pill options actually compare
• Ultra-long-acting monthly GLP-1s - the pipeline is also moving on dosing interval, not just receptor count
• Part of The Complete Guide to GLP-1s

---

Educational content, not medical advice. Pipeline drugs are investigational and not approved unless stated; trial data and timelines change. No doses, schedules or protocols appear as guidance anywhere in this article; trial dose groups are described only as published study arms. Claims for the Malaysian market are subject to MAB requirements.

References

• Obesity pipeline overviews (2026): multi-target agonists, oral and monthly delivery, muscle-preservation focus; candidate list (retatrutide, CagriSema, amycretin, orforglipron, aleniglipron, MariTide, survodutide, VK2735, CT-388, pemvidutide).
• Aleniglipron: randomised, double-blind, placebo-controlled Phase 2b trial in adults with overweight or obesity, Nature Medicine (2026); 230 participants, 38 US sites, 36 weeks; body-weight change from baseline −9.0% / −10.7% / −12.1% across three dose groups; placebo-adjusted −8.2% / −9.8% / −11.3%.
• Retatrutide TRIUMPH programme - highest Phase 3 weight loss in class. Eli Lilly investor release, 23 July 2026 (investor.lilly.com): TRIUMPH-2 (n=1,152, type 2 diabetes, 80 weeks) and TRIUMPH-3 (n=1,949, established cardiovascular disease, 80 weeks) met their primary endpoints versus placebo; CMC package in completion; US BLA submission planned Q1 2027. TRIUMPH-5 (first randomised head-to-head vs tirzepatide, primary outcome percent change in body weight) had not reported as of 26 October 2026; earliest readout 2027 onward.
• CagriSema - Novo Nordisk NDA filed with the FDA 18 December 2025 on REDEFINE-1 and REDEFINE-2 (Novo Nordisk release); first once-weekly GLP-1 + amylin-analogue combination for weight management; no FDA decision as of 26 October 2026, company guidance points to Q4 2026, no public PDUFA date; described as still investigational in coverage dated 23 October 2026. REDEFINE-1: 91.9% of participants achieved ≥5% body-weight reduction vs 31.5% on placebo. REDEFINE-4 did not meet its primary endpoint of non-inferiority on weight loss versus tirzepatide at 84 weeks.
• Oral semaglutide (Wegovy pill) - FDA-approved for long-term weight reduction and maintenance and for reducing the risk of major adverse cardiovascular events; first oral GLP-1 receptor agonist approved for weight management; US launch January 2026; OASIS-4 mean weight loss ~16.6% when treatment was adhered to, broadly comparable to injectable Wegovy.
• Amycretin - Phase 3 advancement; ~22% weight loss at 36 weeks (early data).
• Orforglipron - oral small-molecule GLP-1, FDA-approved as Foundayo (Apr 1, 2026); ~12.4% weight loss at highest dose (ATTAIN).
• Elecoglipron - AstraZeneca press release, 8 June 2026: Phase 2b VISTA and SOLSTICE results presented at ADA 2026 and published in The Lancet; VISTA highest dose arm ~10.5% mean weight reduction at 26 weeks vs ~0.6% placebo, ~11.8% at 36 weeks; SOLSTICE HbA1c −1.9 vs −0.2 percentage points at 26 weeks; advancing into Phase III (EMBOLD, ELUMINATE, plus cardiovascular and kidney outcome trials). Not approved in any market.
• PF'3944 (MET-097i) - Pfizer, Phase 2b VESPER-3 topline (2026): ultra-long-acting injectable GLP-1 RA, weekly-to-monthly maintenance switch, up to ~12.3% mean placebo-adjusted weight loss at week 28; detailed results presented at ADA 2026. Not approved in any market.

Last reviewed: 26 October 2026.